Gu,Y, Jaiswal JK, Wang J, Hicks KO, Hay MP, Wilson WR. Photodegradation of the benzotriazine 1,4-di-N-oxide hypoxia-activated prodrug SN30000 in aqueous solution. J. Pharm. Sci. 103, 3464-3472, 2014. (PMID: 24737463)
Chitneni SK, Bida GT, Yuan H, Palmer GM, Hay MP, Melcher T, Wilson WR, Zalutsky MR, Dewhirst MW. 18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non–small cell lung cancer xenograft model. J Nucl. Med. 54, 1339–1346, 2013. (PMID: 23740105)
Wang J, Foehrenbacher A, Su J, Patel R, Hay MP, Hicks KO, Wilson WR. The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia. Clin. Cancer. Res.18, 1684–1695, 2012. (PMID: 22167409)
Hunter FW, Wang J, Patel R, Hsu H-L, Hickey AJ, Hay MP, Wilson WR. Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with other hypoxia-activated prodrugs. Biochem. Pharmacol. 83, 574–585, 2012. (PMID: 22182429)
Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nature Rev. Cancer 11, 393–410, 2011 (PMID: 21606941).
Hicks KO, Siim BG, Jaiswal JK, Pruijn FB, Fraser AM, Patel R, Hogg A, Liyanage HDS, Dorie MJ, Brown JM, Denny WA, Hay MP, Wilson WR. Pharmacokinetic/ pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors. Clin. Cancer Res. 16, 4946–4957, 2010 (PMID: 20732963).
Yadav PJ, Marshall A, Reynisson J, Denny WA, Hay MP, Anderson RF. Fragmentation of the quinoxaline N-oxide bond to release the •OH radical upon one-electron bioreduction. Chem. Commun. 50, 13729-13731, 2014. (PMID: 25248989)
Anderson RF, Yadav P, Patel D, Reynisson J, Tipparaju SR, Guise CP, Patterson AV. Denny WA, Maroz A, Shinde SS, Hay MP. Characterisation of radicals formed by the anti-tumour compound 3-[3-(4-morpholinyl) propyl]-7,8-dihydro-6H-indeno[5,6-e][1,2,4]triazine 1,4-dioxide, SN30000, a hypoxia-activated prodrug. Org. Biomolec. Chem. 12, 3386-3392, 2014. (PMID: 24737463)
Anderson RF, Shinde SS, Maroz A, Hay MP, Patterson AV, Denny WA. Characterization of radicals formed following enzymatic reduction of 3-substituted analogues of the hypoxia-activated cytotoxin 3-amino-1,2,4 benzotriazine 1,4-dioxide (tirapazamine). J. Am. Chem. Soc. 132, 2591-2599, 2010 (PMID: 20141134).
Shinde SS, Hay MP, Patterson AV, Denny WA, AndersonRF. Spin-trapping of radicals other than the *OH radical upon reduction of the anticancer agent tirapazamine by cytochrome P450 reductase. J. Am. Chem. Soc. 2009, 131, 14220-14221 (PMID: 19772319).